Meridian Wealth Partners’s 10x Genomics TXG Stock Holding History

Meridian Wealth Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	–	–	1181
2021 Q1	$0	Buy	+1	New	+$173	﹤0.01%	1461

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Meridian Wealth Partners's TXG Position: Q2 2021 in Review

Meridian Wealth Partners sold out of 10x Genomics (TXG) in Q2 2021, closing a stake of 1 share.

Meridian Wealth Partners first reported a position in TXG in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 340 funds tracked by Wall St. Rank hold TXG as of Q2 2021.

Meridian Wealth Partners reported no remaining 10x Genomics position as of Q2 2021 after selling out during the quarter.
Meridian Wealth Partners sold 1 10x Genomics share in Q2 2021.
Meridian Wealth Partners first reported a position in 10x Genomics in Q1 2021 and held it in 1 quarter.
Meridian Wealth Partners's 10x Genomics position peaked at $0 in Q1 2021.
340 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2021.

Based on Meridian Wealth Partners's 13F filing for Q2 2021, filed 12 Aug 2021.